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LETTERS TO THE EDITORRegarding “A prospective open-label study of
endovascular treatment of chronic cerebrospinal
venous insufficiency”
I read with great interest the article written by Zamboni et al1
regarding the open-label study of endovascular treatment of
chronic cerebrospinal venous insufficiency (CCSVI) in patients
with multiple sclerosis (MS), which was published in December
2009. The study reports significant reductions in the annualized
relapse rate in 65 MS patients (10 with primary progressive, 35
with relapse remitting, and 20 with secondary progressive) who
underwent treatment of central venous stenosis with measurable
pressure gradients with a mean follow-up of 18 months. The
percent freedom from relapse increased from 27% to 50% (P 
.0014), and the annualized relapse rate fell from 0.9 0.8 to 0.7
1 (P .11). All of the patients were said to be receiving treatment
with a U.S. Food and Drug Administration-approved drug.
Zamboni et al2 also published an article on CCSVI in patients
with MS in the Journal of Neurology, Neurosurgery, and Psychiatry
in 2009. That article, which was received by the journal on July 2,
2008, reports on the central venous pathology in 65 patients with
MS (10 with primary progressive, 35 with relapse remitting, and
20with secondary progressive). In this report, 28 of the 65 patients
(43.1%) were not receiving medical treatment at the time of the
evaluation.
Unfortunately, neither article gives the treatment date range,
but the fact that both articles have the exact same number of MS
patients and the exact same number of patients with primary
progressive, relapse-remitting, and secondary progressive disease
suggests that both of the articles report the same patient pool.
Combining these factual concerns suggest that some, if not all, of
the response to angioplasty is due to initiating medical therapy—
not angioplasty.
This concern is supported by realizing that the annualized
relapse rate for MS patients diagnosed with CCSVI and treated
with angioplasty fell from 0.9  0.8 to 0.7  1.1 This should be
compared with the annual relapse rate for patients treated with
interferon -1a, which is 0.55.3 Based on these relapse rates,
patients receiving approved medical therapy have a lower relapse
rate than those treated with angioplasty.
It is estimated that 350,000 people in the United States have
the diagnosis ofMS,4 of those, 50% require help ambulating within
15 years. The disease is life altering; the suicide risk is high, even in
young patients with mild symptoms.5 If the above concerns are
correct, presenting this procedure as an effective treatment of MS
has created an unfortunate urban myth that desperate MS sufferers
will cling to. The conflict of interest is obvious; the lay press is
already reporting that patients with MS are seeking out physicians
around the world who offer this therapy—for $10,000 per treat-
ment.6
Jay Requarth, MD
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Reply
We thank Dr Requarth for giving us the opportunity to add
further data and discussion to our article. However, he certainly
read with interest—but not carefully—our article, because on page
1350 line 12, we explain that the cohort of patients was the same as
previously reported.1 In the former article about these patients,2
we described chronic cerebrospinal venous insufficiency (CCSVI),
a syndrome demonstrated by the combination of Doppler ultra-
sound imaging and catheter angiography and characterized by
outflow problems of the major extracranial cerebral veins. We also
described the frequent association of CCSVI with multiple sclero-
sis (MS).2
Dr Requarth is right in reporting that the average relapse in
the relapsing remitting clinical course of MS, under disease-
modifying treatment (DMT), is 0.55/year. This particular clinical
course was present in 35 patients of the cohort, and 33 (94%) were
under DMT (Table). The other 26 patients without treatment, as
correctly observed byDr Requarth, were in differentMS categories
and are characterized by clinical courses without relapses, as re-
ported in the last paragraph of page 1349. For instance, the
primary progressive clinical course of MS is actually orphan of any
treatment (10 patients in our cohort), and quite frequently, pa-
tients with severe disability and secondary progressive MS refuse
any treatment because it is completely ineffective (16 patients in
our cohort; Table).3
Table. Treatment used at least once during the previous
3 years in the patient cohort with chronic cerebrospinal
venous insufficiency multiple sclerosis (MS)
Treatment Drug MS cases, No.
Immunosuppressants Mitoxantrone,
cyclophosphamide,
azathioprine
22
Immunomodulators Interferon-,
glatiramer acetate
31
Corticosteroids IV high-dose
methylprednisolone
95a
Treatment refusal 16 SP
2 RR
PP cases No available effective
treatment
10
IV, Intravenous; PP, primary progressive; RR, relapsing remitting; SP,
secondary progressive.
aNo. of cycles of treatment in acute exacerbations.
